KLK3 and cancer: On univariate analysis, ECOG performance status ≤2, chemotherapy naïve, any PSA decline, >50% PSA decline, patients who were pre-treated with ≤2 lines of standard anti-cancer systemic treatment, and patients who were further subjected to anti-cancer treatment post-177Lu-PSMA-617 therapy were associated with significantly prolonged overall survival (Table 3).